Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.60 |
| ▸ | RAB9A | P51151 | 4/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CDK8 | P49336 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | STAT1 | P42224 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1504021 | 0.98 | NPC1 (0.58) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL1012343 | 0.88 | SMN1; SMN2 (0.46) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL1013888 | 0.86 | PRKCZ (0.53) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL4056715 | 0.86 | NPC1 (0.45) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL31265664 | 0.86 | NPC1 (0.45) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL1013244 | 0.86 | CYP2C9 (0.57) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL274692 | 0.86 | NPC1 (0.57) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL1283896 | 0.86 | CDK8 (0.47) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL1264553 | 0.86 | CYP1A2 (0.61) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL15484888 | 0.85 | NPC1 (0.53) | NPC1RAB9ASMN1; SMN2MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 481 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2819998-B1 | CRYSTALLINE FORMS OF 1-(3-TERT-BUTYL-1-P-TOLYL-1H-PYRAZOL-5-YL)-3-(5-FLUORO-2-(1-(2-HYDROXYETHYL)-1H-INDAZOL-5-YLOXY)BENZYL)UREA HYDROCHLORIDE | ARRAY BIOPHARMA INC (US) | 2022-04-06 | — | — | EP | claimed |
| US-9278936-B2 | Crystalline forms of 1-(3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-1H-indazol-5-yloxy)benzyl)urea hydrochloride | ARRAY BIOPHARMA INC. (US) | 2016-03-08 | — | — | US | claimed |
| US-20150030673-A1 | CRYSTALLINE FORMS OF 1-(3-TERT-BUTYL-1-P-TOLYL-1H-PYRAZOL-5-YL)-3-(5-FLUORO-2-(1-(2-HYDROXYETHYL)-INDAZOL-5-YLOXY)BENZYL)UREA HYDROCHLORIDE | ARRAY BIOPHARMA INC. (US) | 2015-01-29 | — | — | US | claimed |
| EP-2819998-A1 | CRYSTALLINE FORMS OF 1- (3 -TERT-BUTYL- 1 - P-TOLYL- 1H- PYRAZOL- 5 -YL) -3- (5-FLUORO-2- (1- ( 2 - HYDROXYETHYL) - INDAZOL- 5 -YLOXY) BENZYL) UREA HYDROCHLORIDE | Array Biopharma, Inc. (US) | 2015-01-07 | — | — | EP | claimed |
| WO-2013130573-A1 | CRYSTALLINE FORMS OF 1- (3 -TERT-BUTYL- 1 - P-TOLYL- 1H- PYRAZOL- 5 -YL) -3- (5-FLUORO-2- (1- ( 2 - HYDROXYETHYL) - INDAZOL- 5 -YLOXY) BENZYL) UREA HYDROCHLORIDE | ARRAY BIOPHARMA INC. (US) | 2013-09-06 | — | — | WO | claimed |
| EP-1670787-A4 | CYTOKINE INHIBITORS | KEMIA INC (US) | 2009-04-22 | — | — | EP | claimed |
| EP-1670787-A2 | CYTOKINE INHIBITORS | Kemia, INC. (US) | 2006-06-21 | — | — | EP | claimed |
| US-20050107399-A1 | Cytokine inhibitors | KEMIA, INC. | 2005-05-19 | — | — | US | claimed |
| WO-2005023761-A2 | CYTOKINE INHIBITORS | KEMIA, INC. (US) | 2005-03-17 | — | — | WO | claimed |
| US-12637463-B2 | Tricyclic kinase inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| EP-4724439-A1 | HETEROARYL DERIVATIVES AS DDRS INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2026-04-15 | — | — | EP | disclosed |
| EP-3774797-B1 | HETEROARYL COMPOUNDS AS TYPE II IRAK INHIBITORS AND USES HEREOF | MERCK PATENT GMBH (DE) | 2025-11-19 | — | — | EP | disclosed |
| EP-4313293-B1 | TETRAHYDROTHIENO PYRIDINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARM SPA (IT) | 2025-05-07 | — | — | EP | disclosed |
| WO-2025067411-A1 | NEK7 INHIBITOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 北京普祺医药科技股份有限公司 | 2025-04-03 | — | — | WO | disclosed |
| EP-1435936-A1 | 5'-CARBAMOYL-1,1-BIPHENYL-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-07-14 | — | — | EP | disclosed |
| US-20040023961-A1 | Aryl ureas with raf kinase and angiogenisis inhibiting activity | BAYER CORPORATION | 2004-02-05 | — | — | US | disclosed |
| US-20030232865-A1 | 1,4-Benzofused urea compounds useful in treating cytokine mediated diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-12-18 | — | — | US | disclosed |
| WO-2003072569-A1 | 1,4-DISUBSTITUTED BENZOFUSED CYCLOALKYL UREA COMPOUNDS USEFUL IN TREATING CYTOKINE MEDIATED DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-09-04 | — | — | WO | disclosed |
| WO-2003068223-A1 | ARYL UREAS WITH RAF KINASE AND ANGIOGENESIS INHIBITING ACTIVITY | BAYER CORPORATION (US) | 2003-08-21 | — | — | WO | disclosed |
| WO-2003032972-A1 | 5’-CARBAMOYL-1,1-BIPHENYL-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107399-A1 | Cytokine inhibitors | TNF, IL1RN, IL1A | NPC1 4360/4885RAB9A 2499/4885SMN1; SMN2 4806/4885 |
| US-12637463-B2 | Tricyclic kinase inhibitors and uses thereof | CDK1, CDK11A, CDK11B | NPC1 1147/4885RAB9A 2872/4885SMN1; SMN2 2356/4885 |
| US-20030232865-A1 | 1,4-Benzofused urea compounds useful in treating cytokine mediated diseases | IL1A, IL1B, XDH | NPC1 2892/4885RAB9A 2451/4885SMN1; SMN2 3891/4885 |
| US-20150030673-A1 | CRYSTALLINE FORMS OF 1-(3-TERT-BUTYL-1-P-TOLYL-1H-PYRAZOL-5-YL)-3-(5-FLUORO-2-(1-(2-HYDROXYETHYL)-INDAZOL-5-YLOXY)BENZYL)UREA HYDROCHLORIDE | TTR, HK1, REN | NPC1 196/4885RAB9A 390/4885SMN1; SMN2 3345/4885 |
| US-20040023961-A1 | Aryl ureas with raf kinase and angiogenisis inhibiting activity | BRAF, FLT1, RAF1 | NPC1 3010/4885RAB9A 1628/4885SMN1; SMN2 4589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.